Sinovac Biotech Co., Ltd: Pneumococcal Infections trials

The registry lists 13 Pneumococcal Infections studies with Sinovac Biotech Co., Ltd as lead sponsor. 3 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 2Phase 3 2Phase 4 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 YearsRecruitingNCT07300644Phase 2
• Clinical Trial of PCV24 in Infants Aged 2-23 MonthsRecruitingNCT06800261Phase 1
• Clinical Trial of 13-Valent Pneumococcal Conjugate VaccineRecruitingNCT06617715Phase 3
• Clinical Trial of PCV24 in Adults Aged ≥18 YearsCompletedNCT07543198Phase 1/2
• A Clinical Trial to Observe the Safety of 23-Valent Pneumococcal Polysaccharide Vaccine in Target PopulationCompletedNCT07071701
• Clinical Trial of PCV24 in Children Aged 2-17 YearsCompletedNCT06550830Phase 1
• Clinical Trial of PCV24 in AdultsCompletedNCT06474377Phase 1
• A Phase 1b Clinical Trial of 13-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedNCT06183216Phase 1
• Lot-to-lot Consistency of 23-valent Pneumococcal Polysaccharide VaccineCompletedNCT05731115Phase 4
• Immunogenicity and Safety of 23-valent Pneumococcal Polysaccharide VaccineCompletedNCT05477693Phase 4
• Safety and Immunogenicity Study of a 13-valent Pneumococcal Polysaccharide Conjugate VaccineCompletedNCT05092386Phase 1
• A Clinical Trial of 23-valent Pneumococcal Polysaccharide VaccineCompletedNCT04989465Phase 4
• Safety and Immunogenicity Study of 23-valent Pneumococcal Polysaccharide Vaccine in Healthy Children, Adults and ElderlyCompletedNCT02451969Phase 3